Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
暂无分享,去创建一个
Federico Corelli | Simone Brogi | Andrea Tafi | Vincenzo Di Marzo | Simone Brogi | V. Di Marzo | A. Ligresti | F. Corelli | A. Tafi | C. Mugnaini | S. Pasquini | Alessia Ligresti | Serena Pasquini | Claudia Mugnaini
[1] S. Nikas,et al. Novel 1′,1′-chain substituted Δ8-tetrahydrocannabinols , 2002 .
[2] Serdar Durdagi,et al. The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2. , 2007, Journal of medicinal chemistry.
[3] Michael Koblish,et al. Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability. , 2010, Bioorganic & medicinal chemistry letters.
[4] S. Durdağı,et al. A computational study on cannabinoid receptors and potent bioactive cannabinoid ligands: homology modeling, docking, de novo drug design and molecular dynamics analysis , 2010, Molecular Diversity.
[5] R. Pertwee,et al. Therapeutic Applications for Agents that Act at CB1 and CB2 Receptors , 2009 .
[6] P. Lazzari,et al. Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. , 2006, Journal of medicinal chemistry.
[7] P. Soubrié,et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.
[8] E. Novellino,et al. Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. , 2008, Journal of medicinal chemistry.
[9] P. Chandran,et al. Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. , 2010, Journal of medicinal chemistry.
[10] G. Hynd,et al. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. , 2005, Bioorganic & medicinal chemistry.
[11] R. Dolle,et al. Simultaneous optimization of potency, selectivity and physicochemical properties for cannabinoid CB(2) ligands. , 2009, Current pharmaceutical design.
[12] G. Fox,et al. Characterization of a Cannabinoid CB2 Receptor-Selective Agonist, A-836339 [2,2,3,3-Tetramethyl-cyclopropanecarboxylic Acid [3-(2-Methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], Using in Vitro Pharmacological Assays, in Vivo Pain Models, and Pharmacological Magnetic Resonance Imaging , 2009, Journal of Pharmacology and Experimental Therapeutics.
[13] Qian Liu,et al. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach. , 2006, Journal of medicinal chemistry.
[14] Michael Koblish,et al. CB2 selective sulfamoyl benzamides: optimization of the amide functionality. , 2009, Bioorganic & medicinal chemistry letters.
[15] G. Gessa,et al. Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors. , 2004, Bioorganic & medicinal chemistry.
[16] Michael Koblish,et al. Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists. , 2009, Bioorganic & medicinal chemistry letters.
[17] G. Cruciani,et al. A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors. , 2000, Journal of Medicinal Chemistry.
[18] A. Makriyannis,et al. Novel conformationally restricted tetracyclic analogs of delta8-tetrahydrocannabinol. , 1999, Bioorganic & medicinal chemistry letters.
[19] R. Pertwee,et al. Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630 , 1999, British journal of pharmacology.
[20] G. Velasco,et al. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? , 2007, Trends in pharmacological sciences.
[21] I. Chessell,et al. Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. , 2007 .
[22] S. Yu,et al. 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. , 1999, Bioorganic & medicinal chemistry.
[23] T. Bonner,et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.
[24] P. Casellas,et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.
[25] L. Petrocellis,et al. The endocannabinoid system and its therapeutic exploitation , 2004, Nature Reviews Drug Discovery.
[26] H. Iwamura,et al. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. , 2001, The Journal of pharmacology and experimental therapeutics.
[27] R. Mechoulam,et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[28] Thierry Langer,et al. Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. , 2009, Journal of medicinal chemistry.
[29] Y. Toda,et al. N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability. , 2007, Bioorganic & medicinal chemistry letters.
[30] Alexandros Makriyannis,et al. Structural biology of human cannabinoid receptor-2 helix 6 in membrane-mimetic environments. , 2009, Biochemical and biophysical research communications.
[31] Gerhard Klebe,et al. 3D QSAR Selectivity Analyses of Carbonic Anhydrase Inhibitors: Insights for the Design of Isozyme Selective Inhibitors , 2006, J. Chem. Inf. Model..
[32] M. Krishnamurthy,et al. Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. , 2008, Bioorganic & medicinal chemistry.
[33] R. Razdan,et al. Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. , 2002, The Journal of pharmacology and experimental therapeutics.
[34] S. Munro,et al. Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.
[35] F. Mauler,et al. 3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): A Novel Cannabinoid CB1/CB2 Receptor Partial Agonist with Antihyperalgesic and Antiallodynic Effects , 2004, Journal of Pharmacology and Experimental Therapeutics.
[36] L. Koetzner,et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy , 2005, Neuropharmacology.
[37] R. Pertwee,et al. O‐1057, a potent water‐soluble cannabinoid receptor agonist with antinociceptive properties , 2000, British journal of pharmacology.
[38] Philippe Chavatte,et al. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. , 2006, Journal of medicinal chemistry.
[39] David E. Shaw,et al. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results , 2006, J. Comput. Aided Mol. Des..
[40] J. Lange,et al. Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies. , 2010, Bioorganic & medicinal chemistry letters.
[41] R. Pertwee,et al. Pharmacology of cannabinoid receptor ligands. , 1999, Current medicinal chemistry.
[42] Y. Toda,et al. Sulfonamide derivatives as new potent and selective CB2 cannabinoid receptor agonists. , 2007, Bioorganic & medicinal chemistry letters.
[43] M. Cascio,et al. In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists. , 2010, Pharmacological research.
[44] M. Cascio,et al. Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands. , 2010, Journal of medicinal chemistry.
[45] D. Cockayne,et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[46] R. Pertwee,et al. Emerging strategies for exploiting cannabinoid receptor agonists as medicines , 2009, British journal of pharmacology.
[47] P. Pacher,et al. The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.
[48] L. Botta,et al. Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo. , 2008, Journal of medicinal chemistry.
[49] Wei Li,et al. Synthesis and testing of novel classical cannabinoids: exploring the side chain ligand binding pocket of the CB1 and CB2 receptors. , 2003, Bioorganic & medicinal chemistry.
[50] A. Howlett. The cannabinoid receptors. , 2002, Prostaglandins & other lipid mediators.
[51] A. Malikzay,et al. Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors. , 2010, Bioorganic & medicinal chemistry letters.
[52] A. Makriyannis,et al. Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? , 2009, Trends in pharmacological sciences.
[53] D. Bashford,et al. Quantitative structure-activity relationship (QSAR) for a series of novel cannabinoid derivatives using descriptors derived from semi-empirical quantum-chemical calculations. , 2009, Bioorganic & medicinal chemistry.
[54] V. Marzo,et al. Targeting the endocannabinoid system: to enhance or reduce? , 2008, Nature Reviews Drug Discovery.
[55] Y. Toda,et al. Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action. , 2008, Bioorganic & medicinal chemistry.
[56] Andrew J. Brown,et al. Synthesis and evaluation of 3-amino-6-aryl-pyridazines as selective CB(2) agonists for the treatment of inflammatory pain. , 2010, Bioorganic & medicinal chemistry letters.
[57] P. Fossa,et al. CoMFA and CoMSIA analyses on 4-oxo-1,4-dihydroquinoline and 4-oxo-1,4-dihydro-1,5-, -1,6- and -1,8-naphthyridine derivatives as selective CB2 receptor agonists , 2010, Journal of molecular modeling.
[58] N. Romeiro,et al. Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors. , 2009, European journal of medicinal chemistry.